This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Sarah Hoagland
Sarah M. Hoagland
Of Counsel
Washington +1 202 662 5351 Download V-card

Sarah Hoagland is of counsel in the Corporate and Life Sciences practice groups.  Her practice focuses on transactions for pharmaceutical and biotechnology clients, including licensing and collaboration arrangements, acquisitions and divestitures of pharmaceutical companies and products, marketing and co-promotion agreements, and supply and distribution transactions.

  • AbbVie in a novel collaboration with the Google-backed life sciences start-up company Calico focused on aging and age-related diseases, such as cancer and neurodegenerative diseases. 
  • Eli Lilly in its agreement to terminate its alliance with Amylin Pharmaceuticals for Byetta and Bydureon and to resolve the outstanding litigation between the companies, involving a two-year transition of responsibilities outside the US and payments of up to $1.6 billion.
  • AstraZeneca:
    • in connection with its agreement granting Pfizer worldwide rights to sell an OTC version of AstraZeneca’s blockbuster proton pump inhibitor, Nexium;
    • in connection with its global collaboration with The Medicines Company to develop and commercialize acute ischemic heart disease compounds;
    • in an exclusive, worldwide collaboration with Targacept, Inc. to develop and commercialize a late-stage investigational product for major depressive disorder, which involved upfront fees, milestones and funding commitments in excess of $1 billion;
    • in connection with a co-promotion agreement with Abbott Laboratories for AstraZeneca's CRESTOR®;
    • in its acquisition of assets relating to the mGluR receptors collaboration between AstraZeneca and NPS Pharmaceuticals; and
    • in a collaboration with Bristol-Myers Squibb Company to develop and commercialize two different products for the treatment diabetes.
  • Eisai:
    • in connection with a marketing and supply agreement with Arena Pharmaceuticals, Inc. for the exclusive right to commercialize lorcaserin for obesity and weight management in the United States;
    • in the acquisition by Morphotek, Inc. (a subsidiary of Eisai Inc.) of certain assets relating to a proprietary tumor targeting platform from TransMolecular, Inc.; and
    • in connection with a strategic drug discovery collaboration with Forma Therapeutics pursuant to which Eisai obtains non-exclusive access to Forma’s Diversity Oriented Synthesis chemistry-generated compound library and cell-based screening platforms to support the discovery of novel compounds for Eisai’s pipeline and an option for technology transfer of Forma’s cell-based screening platform. 
  • UCB in connection with a strategic partnership pursuant to which it granted rights to Wilex AG, a German biotechnology company, with respect to a preclinical oncology portfolio, comprising two small-molecule programs and three antibody programs, and retained rights to reacquire such programs following completion of initial clinical feasibility studies.
  • A biotechnology company in support of all aspects of contracting with respect to its pivotal clinical trial anticipated to involve over 100 sites in the United States, Europe and Canada, including CRO arrangements and clinical trial agreements.

Pro Bono

  • Sabin Vaccine Institute in negotiating certain manufacturing arrangements in support of its clinical trial program.
  • Legal 500 US, Healthcare - Life Sciences (2016); Patents - Portfolio Management and Licensing (2015-2016); and Media, Technology and Telecoms - Technology - Transactions (2015)
  • Washington DC Super Lawyers, Corporate "Rising Star" (2014)